Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway (Q34290152)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway (English)

1 reference

Europe PubMed Central

1 August 2017

0 references

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

author name string

Chun-Jie Han

1

1 reference

Europe PubMed Central

1 August 2017

Jun-Tian Liu

2

1 reference

Europe PubMed Central

1 August 2017

Ming Li

3

1 reference

Europe PubMed Central

1 August 2017

Mu Cui

4

1 reference

Europe PubMed Central

1 August 2017

Xiao-Ming Pang

5

1 reference

Europe PubMed Central

1 August 2017

Jun-Jun Mao

6

1 reference

Europe PubMed Central

1 August 2017

Xiao-Fang Liu

7

1 reference

Europe PubMed Central

1 August 2017

publication date

3 June 2012

1 reference

Europe PubMed Central

1 August 2017

Inflammation Research

1 reference

Europe PubMed Central

1 August 2017

61

1 reference

Europe PubMed Central

1 August 2017

9

1 reference

Europe PubMed Central

1 August 2017

1031-1037

1 reference

Europe PubMed Central

1 August 2017

https://scigraph.springernature.com/pub.10.1007/s00011-012-0496-9

0 references

Inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

C-reactive protein: risk marker or mediator in atherothrombosis?

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction.

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

C-Reactive Protein Decreases Prostacyclin Release From Human Aortic Endothelial Cells

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Generation of C-reactive protein and complement components in atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Angiotensin II induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic endothelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Antiinflammatory and antiarteriosclerotic effects of pioglitazone

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Saga of renin-angiotensin system and calcium channels in hypertensive diabetics: does it have a therapeutic edge?

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

High glucose enhances angiotensin-II-mediated peroxisome proliferation-activated receptor-gamma inactivation in human coronary artery endothelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Peroxisome proliferator-activated receptors and cardiovascular remodeling

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

NADPH oxidase-derived superoxide anion mediates angiotensin II-induced pressor effect via activation of p38 mitogen-activated protein kinase in the rostral ventrolateral medulla

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway.

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

Role of reactive oxygen species-sensitive extracellular signal-regulated kinase pathway in angiotensin II-induced endothelin-1 gene expression in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00011-012-0496-9

21 January 2018

The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22659808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22659808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22659808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leptin induces C-reactive protein expression in vascular endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22659808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22659808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22659808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00011-012-0496-9

1 reference

Europe PubMed Central

1 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34290152&oldid=1545261391"